Abstract:Rejection of solid organ transplant and graft versus host disease (GvHD) continue to be challenging in post transplantation management. The introduction of calcineurin inhibitors dramatically improved recipients' short-term prognosis. However, long-term clinical outlook remains poor, moreover, the lifelong dependency on these toxic drugs leads to chronic deterioration of graft function, in particular the renal function, infections and de-novo malignancies. These observations led investigators to identify alternative therapeutic options to promote long-term graft survival, which could be used concomitantly, but preferably, replace pharmacologic immunosuppression as standard of care. Adoptive T cell (ATC) therapy has evolved as one of the most promising approaches in regenerative medicine in the recent years. A range of cell types with disparate immunoregulatory and regenerative properties are actively being investigated as potential therapeutic agents for specific transplant rejection, autoimmunity or injury-related indications. A significant body of data from preclinical models pointed to efficacy of cellular therapies. Significantly, early clinical trial observations have confirmed safety and tolerability, and yielded promising data in support of efficacy of the cellular therapeutics. The first class of these therapeutic agents commonly referred to as advanced therapy medicinal products have been approved and are now available for clinical use. Specifically, clinical trials have supported the utility of CD4 + CD25+FOXP3+ regulatory T cells (Tregs) to minimize unwanted or overshooting immune responses and reduce the level of pharmacological immunosuppression in transplant recipients. Tregs are recognized as the principal orchestrators of maintaining peripheral tolerance, thereby blocking excessive immune responses and prevent autoimmunity. Here, we summarize rationale for the adoptive Treg therapy, challenges in manufacturing and clinical experiences with this novel living drug and outline future perspectives of its use in transplantation.

Regulatory T Cell Therapy for the Induction of Clinical Organ Transplantation Tolerance

Gut Microbes Enlarged the Protective Effect of Transplanted Regulatory B Cells on Rejection of Cardiac Allografts.

Impact of Regulatory T Cells on Innate Immune Cells in a Pre-Sensitized Heart Transplant Model

T Regulatory Cells As an Immunotherapy for Transplantation

CD4+CD25+ regulatory T cell therapy for the induction of donor-specific clinical transplantation tolerance.

T regulatory cells as an immunotherapy for transplantation.

Regulatory T cells and transplantation tolerance.

Regulating Regulatory T Cells to Achieve Transplant Tolerance.

Regulatory T Cells in Transplantation Tolerance

Antigen Specific Regulatory T Cells in Kidney Transplantation and Other Tolerance Settings

Graft-Specific Regulatory T Cells for Long-Lasting, Local Tolerance Induction

Transfer of Regulatory T Cells Generated Ex Vivo Modifies Graft Rejection Through Induction of Tolerogenic CD4+CD25+ Cells in the Recipient

The Critical Role of Induced CD4+ FoxP3+ Regulatory Cells in Suppression of Interleukin-17 Production and Attenuation of Mouse Orthotopic Lung Allograft Rejection.

Induced Regulatory T Cells as Immunotherapy in Allotransplantation and Autoimmunity: Challenges and Opportunities

Role and mechanisms of CD4+CD25+ regulatory T cells in the induction and maintenance of transplantation tolerance.

Adoptive Transfer of Regulatory Immune Cells in Organ Transplantation

Clinical adoptive regulatory T Cell therapy: State of the art, challenges, and prospective

Role of CD8+ Regulatory T Cells in Organ Transplantation

Regulatory-B Cell and Regulatory-T Cell Collaborate to Promote Transplantation Tolerance (126.2)

Strategies to Achieve Immune Tolerance in Allogeneic Solid Organ Transplantation.

Guiding regulatory T cells to the allograft